---
{"dg-publish":true,"permalink":"/jethro-s-working-notes/cpr-57-drugs-used-in-treatment-of-airway-disease/","dgPassFrontmatter":true}
---


# CPR57: Drugs used in treatment of airway disease

Created: March 28, 2022 5:02 PM
Module: Cardiopulmonary disease
Tags: CPRS
Updated: September 20, 2022 9:19 PM

### Drugs in treatment for asthma

- **Therapeutic goals for treating asthma**
    1. Bronchodilation
    2. Decrease inflammatory response
- Bronchodilators
    - Beta-2 receptor agonist (First line drug in asthma therapy)
        - **Types and examples of beta-2 agonist in asthma therapy**
            
            Short-acting beta-2 agonist (SABA) - Salbutalol, terbutaline
            
            Long-acting beta-2 agonist (LABA) - Salmeterol, Formoterol
            
        - **MOA of beta-2 agonist in asthma therapy**
            
            Binds to beta-2 receptor on smooth muscle cells, resulting in activation of adenyl cyclase, resulting in increased cAMP production
            
            cAMP activates protein kinase A, which phosphorylate MLCK, causing decreased MLCK activity
            
            This results in smooth muscle relaxation and bronchodilation
            
            It also decreases vascular permeability and oedema
            
            It stimulates airway clearance by stimulating mucocilliary apparatus
            
        - **Benefits and use cases of SABA and LABA**
            
            SABA:
            
            4-6 hours 
            
            Rapid relief of symptoms during exacerbations
            
            LABA:
            
            >12 hours
            
            Less symptoms and exacerbations
            
            Improved quality of life
            
            ![[/Screenshot 2022-03-28 at 5.55.33 PM.png\|/Screenshot 2022-03-28 at 5.55.33 PM.png]]
            
        - **Administrative routes of beta-2 receptor agonist**
            
            Inhalation route for management of chronic asthma
            
            Intravenous route for exacerbations (administer SABA and epinephrine)
            
        - **Adverse effects of beta-2 receptor agonist**
            
            Tachycardia
            
            Tremors
            
            Hypokalemia (due to increased Na+/K+ pump)
            
            Development of:
            
            Dessensitization (tachyphylaxis and tolerance) - due to uncoupling of G proteins
            
            Down-regulation of Beta-2 receptors - due to degradation of receptors
            
    - Phosphodiesterase inhibitors/Methylxanthine (Second line drug in asthma therapy)
        - **Examples of PDE inhibitors in asthma therapy**
            
            Theophylline, aminophylline
            
        - **MOA of PDE inhibitors**
            
            Inhibit PDE:
            
            PDE inhibitors inhibits breakdown of cAMP into 5â€™-AMP by PDE
            
            This results in increased cAMP levels, activating protein kinase A
            
            Protein kinase A phosphorylates MLCK, resulting in decreased MLCK activity, resulting in relaxation and bronchodilations
            
            Block adenosine receptors:
            
            Prevents mast cell degranulation and histamine release
            
            Prevent contraction of smooth muscles
            
        - **Adverse effects of PDE inhibitors**
            
            CNS effect - cause nervousness
            
            Cardiovascular effect - chronotropic and inotropic effects
            
            GI effects - stimulate secretion by GI tract, causing nausea and vomiting
            
            Kidney - Diuresis
            
    - Muscarinic receptor antagonist
        - **Types and examples of muscarinic receptor antagonists**
            
            Short-acting muscarinic receptor antagonist (SAMA) - ipratropium
            
            Long-acting muscarinic receptor antagonist (LAMA) - tiotropium
            
        - **MOA of muscarinic receptor antagonists**
            
            Block muscarinic receptors on airway smooth muscles, thus decreasing vagal cholinergic activity
            
            This causes decreased mucus secretion and decreased bronchoconstriction
            
        - **Adverse effects of muscarinic receptor antagonist**
            
            Dry mouth
            
            Irritating cough
            
- Leukotriene pathway modifiers
    - **Types and examples of Leukotriene pathway modifiers in asthma therapy**
        
        Cysteinyl leukotriene receptor antagonists - Montelukast, Zafirlukast
        
        5-lipoxygenase inhibitors - Zileuton
        
    - **MOA of different types of leukotriene pathway modifiers in asthma therapy**
        
        Cysteinyl leukotriene receptor antagonists:
        
        Block LTC4 and LTD4 receptors to prevent LTC4 and LTD4 mediated bronchospasm
        
        5-lipoxygenase inhibitors:
        
        Inhibits sinthesis of leukotrienes to inhibit bronchospasm
        
    - **Clinical use of leukotriene pathway modifiers**
        
        As an add-on therapy for asthma, taken orally
        
    - **Adverse effects of leukotriene pathway modifiers**
        
        Nausea
        
        Diarrhea
        
        Headaches
        
- Antiinflammatory drugs (glococortisoids)
    - **MOA of glucocortisoids in asthma therapy**
        
        Gluccocortisoids bind to gluccosteroid receptors, resulting in several effects:
        
        Broad anti-inflammatory actions:
        
        Decrease synthesis and release of inflammatory cytokines by epithelial cells and macrophages
        
        Decrease number and activity of inflammatory cells
        
        Decreased oedema of the airway mucosa
        
        Decreased mucus production
        
        Increased expression of beta-2 receptors on airway smooth muscles and their responsiveness to beta-2 agonists:
        
        Thus preventing desensitization and decreased number of beta-2 receptors as a result of beta-2 receptor agonist therapy
        
        ![[/Screenshot 2022-03-30 at 10.18.54 AM.png\|/Screenshot 2022-03-30 at 10.18.54 AM.png]]
        
        Ref: [[Katzung Pharmacology  MOA of corticosteroids in asthma therapy\|Katzung Pharmacology  MOA of corticosteroids in asthma therapy]] 
        
    - **Examples of glucocortisoids and their administrative route**
        
        Inhaled - Budesonide, Fluticasone, Mometasone, Ciclesonide
        
        Oral - Prednisolone, Prednisone
        
        IV - Hydrocortisone
        
        IV route used for exacerbations
        
        Oral and inhaled route used for management of chronic asthma
        
        Ref: [[Katzung Pharmacology  Clinical use of corticosteroids in asthma therapy\|Katzung Pharmacology  Clinical use of corticosteroids in asthma therapy]] 
        
    - **Adverse effects of gluccocortisoids**
        
        Osteoporosis
        
        Cataracts
        
        Glucose intolerance
        
        Depressed immunity
        
        Cushingoid changes - facial roundness, weight gain, darkened skin tone
        
- Antiallergic drugs
    - **Examples of antiallergic drugs in asthma therapy**
        
        Mast cell stabilizers - cromolyn sodium, nedocromil sodium
        
    - **MOA of antiallergic drugs in asthma therapy**
        
        Inhibits mast cell degranulation
        
        Depress neuronal reflex triggered by irritant receptors in the airway
        
    - **Clinical use of antiallergic drugs in asthma therapy**
        
        Prophylactic treatment
        
    - **Administrative route of antiallergic drugs in asthma therapy**
        
        Inhalation route
        
    - **Adverse effects of antiallergic drugs**
        
        Dry mouth
        
        Irritant cough
        
- Targeted therapy (Monoclonal antibodies)
    - Anti-IgE monoclonal antibody
        - **Examples of anti-IgE monoclonal antibody**
            
            Omalizumab
            
        - **MOA of anti-IgE monoclonal antibody**
            
            Reduce circulating levels of IgE, resulting in downregulation of receptors for Fc region of IgE on mast cells, thus inhibiting mast cell degranulation
            
        - **Clinical use of anti-IgE monoclonal antibody and administrative route**
            
            Add on therapy
            
            Prophylactic treatment for patients with severe uncontrolled asthma
            
            Given by subcutaneous injection every 2 to 4 weeks
            
        - **Adverse effects of anti-IgE monoclonal antibody**
            
            Anaphylaxis
            
    - Cytokine-targeted asthma therapies
        - Anti-IL-5 therapy agents
            - **Example of Anti-IL-5 therapy agents**
                
                Humanized monoclonal antibodies targeting IL-5 - mepolizumab, reslizumab
                
                Humanized monoclonal antibodies against IL-5 receptors - benralizumab
                
            - **MOA of anti-IL-5 therapy agents in asthma therapy**
                
                Inhibit IL-5 mediated recruitment and activation of eosinophils
                
                This can be used to treat severe eosinophilic asthma
                
                
<div class="transclusion internal-embed is-loaded"><div class="markdown-embed">





# Untitled

Created: August 28, 2022 9:50 PM
Updated: August 28, 2022 9:50 PM

</div></div>

                
        - Anti-IL-4 therapy agents
            - **Examples of anti-IL-4 therapy agents**
                
                Dupilumab
                
            - **MOA of anti-IL-4 therapy agents**
                
                Monoclonal antibodies directed against IL-4 receptors
                
                This inhibits IgE production, and thus mast cell degranulation
                
            - **Adverse effects of anti-IL-4 therapy agents**
                
                Headaches
                
                Diarrhea
                
                Local reactions
                
- Combination therapy for asthma management
    
    Dual therapy: ICS + LABA
    
    ICS reverse and restores beta-2 receptor function and number
    
    - Pharmacological management for asthma
        
        ![[/Screenshot 2022-03-30 at 11.54.24 AM.png\|/Screenshot 2022-03-30 at 11.54.24 AM.png]]
        

### Drugs in management for COPD

- **Goals for managing COPD**
    
    ![[/Screenshot 2022-03-30 at 11.29.06 AM.png\|/Screenshot 2022-03-30 at 11.29.06 AM.png]]
    
- Bronchodilators
    - Beta-2 agonist
        - **Beta-2 agonist used in COPD and not asthma**
            
            Ultra long acting beta-2 agonist - Indacaterol
            
    - Muscarinic antagonist
        - **Muscarinic antagonist used in COPD and not asthma**
            
            Ultra long acting muscarinic antagonist - Glycopyrronium
            
- Antiinflammatory drugs
    - Glucocortisoids
        - **Mechanism for glucocortisoid resistance in COPD**
            
            In normal conditions:
            
            Glucocortisoids stimulate HDAC3 (histone deacetylase) which reverses histone acetylation by NF-keppaB, thus decreasing the activity of NF-keppaB
            
            Thus decreasing expression of IL-8 and TNF-alpha
            
            In COPD:
            
            Oxidative stress from cigarette smoke (peroxynitrite) reacts with HDAC3, thus it cannot reverse histone acetylation by NF-keppaB
            
            ![[/Screenshot 2022-03-30 at 11.52.18 AM.png\|/Screenshot 2022-03-30 at 11.52.18 AM.png]]
            
    - Selective PDE4 inhibitors
        - **Examples of PDE4 inhibitors in COPD management**
            
            Roflumilast
            
        - **MOA of PDE4 inhibitors**
            
            Inhibits cytokine release by neutrophils and macrophages, thus results in antiinflammatory effect
            
    - Theophylline (still in clinical trial)
- Combined therapy in COPD management
    - Dual therapy
        
        Muscarinic antagonist + beta-2 agonist
        
        Glucocorticoids + beta-2 agonists (less effective for COPD due to glucocortisoid resistance in COPD)
        
        
<div class="transclusion internal-embed is-loaded"><div class="markdown-embed">





# Untitled

Created: August 28, 2022 9:50 PM
Updated: August 28, 2022 9:50 PM

</div></div>

        
    - Triple therapy
        
        ICS + LAMA + LABA (not available in HK)
        
        
<div class="transclusion internal-embed is-loaded"><div class="markdown-embed">





# Untitled

Created: August 28, 2022 9:50 PM
Updated: August 28, 2022 9:50 PM

</div></div>
